PharmaEngine Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

PharmaEngine şirketinin toplam hissedar öz sermayesi NT$3.9B ve toplam borcu NT$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla NT$4.2B ve NT$327.7M dir. PharmaEngine 'in FAVÖK'ü NT$353.7M faiz karşılama oranı -5.6 dur. Şirketin NT$3.9B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

NT$0

Borç

Faiz karşılama oranı	-5.6x
Nakit	NT$3.88b
Eşitlik	NT$3.89b
Toplam yükümlülükler	NT$327.68m
Toplam varlıklar	NT$4.22b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Would PharmaEngine, Inc. (GTSM:4162) Be Valuable To Income Investors?

Mar 30

How Much Did PharmaEngine's(GTSM:4162) Shareholders Earn From Share Price Movements Over The Last Five Years?

Feb 18

Is PharmaEngine, Inc.'s (GTSM:4162) Stock On A Downtrend As A Result Of Its Poor Financials?

Jan 14

We're Not Counting On PharmaEngine (GTSM:4162) To Sustain Its Statutory Profitability

Dec 10

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4162 'nin kısa vadeli varlıkları ( NT$4.2B ) kısa vadeli yükümlülüklerini ( NT$320.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: 4162 şirketinin kısa vadeli varlıkları ( NT$4.2B ) uzun vadeli yükümlülüklerini ( NT$7.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4162 borçsuzdur.

Borcun Azaltılması: 4162 son 5 yıldır borcu bulunmamaktadır.

Borç Kapsamı: 4162 un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 4162 şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

PharmaEngine Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Investor sentiment improves as stock rises 18%

PharmaEngine, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Now 21% overvalued

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Dividend sustainability

Dividend reduced to NT$1.50

PharmaEngine, Inc. to Report Q2, 2024 Results on Jul 25, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of PEP07 for Solid Tumors

PharmaEngine, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Full year 2023 earnings released: EPS: NT$1.91 (vs NT$2.22 in FY 2022)

New major risk - Revenue and earnings growth

PharmaEngine, Inc., Annual General Meeting, May 24, 2024

Third quarter 2023 earnings: Revenues and EPS in line with analyst expectations

New minor risk - Share price stability

Investor sentiment improves as stock rises 22%

TFDA Approves PharmaEngine, Inc.'s PEP07 Phase I Clinical Trial for Solid Tumor Cancers

Upcoming dividend of NT$2.00 per share at 2.4% yield

Second quarter 2023 earnings released: EPS: NT$0.52 (vs NT$0.56 in 2Q 2022)

New major risk - Revenue and earnings growth

PharmaEngine, Inc. Announces EMAs Acceptance of Onivyde's Type II Variation Application

New major risk - Dividend sustainability

PharmaEngine, Inc. Announces Approval of Phase 1 Clinical Study of Pep07 by TFDA

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased to NT$107

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Now 20% undervalued

PharmaEngine, Inc. Announces Change of Board of Directors Chairperson

PharmaEngine, Inc. Announces Management Changes, Effective September 1, 2022

Investor sentiment improved over the past week

Upcoming dividend of NT$2.70 per share

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Pharmaengine, Inc. Announces Dividend for 2021,Payment Date of Cash Dividend Distribution Is September 2, 2022

Consensus revenue estimates increase by 10%

Investor sentiment improved over the past week

Pharmaengine, Inc. Approves the Change of the Member of Compensation Committee

Now 25% undervalued

First quarter 2022 earnings: EPS exceeds analyst expectations

Price target decreased to NT$73.50

Less than half of directors are independent

Investor sentiment improved over the past week

PharmaEngine, Inc., Annual General Meeting, May 27, 2022

Now 21% undervalued

Third quarter 2021 earnings released: EPS NT$0.51 (vs NT$0.13 in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$1.14 (vs NT$0.099 in 2Q 2020)

First quarter 2021 earnings released: EPS NT$0.52 (vs NT$0.34 in 1Q 2020)

Would PharmaEngine, Inc. (GTSM:4162) Be Valuable To Income Investors?

Full year 2020 earnings released: EPS NT$4.15 (vs NT$0.29 in FY 2019)

PharmaEngine, Inc., Annual General Meeting, May 31, 2021

NANOBIOTIX and PharmaEngine, Inc. Mutually Agree to Conclude Collaboration

New 90-day high: NT$66.90

How Much Did PharmaEngine's(GTSM:4162) Shareholders Earn From Share Price Movements Over The Last Five Years?

New 90-day low: NT$48.60

Is PharmaEngine, Inc.'s (GTSM:4162) Stock On A Downtrend As A Result Of Its Poor Financials?

New 90-day low: NT$53.70

Analysts lower revenue estimates to NT$384.0m

We're Not Counting On PharmaEngine (GTSM:4162) To Sustain Its Statutory Profitability

New 90-day low: NT$53.90

Revenue and earnings beat expectations

Third quarter 2020 earnings released: EPS NT$0.13

New 90-day low: NT$56.70

New 90-day low: NT$59.10

New 90-day low: NT$64.70

First half earnings released

First half earnings released

Upcoming Dividend of NT$0.50 Per Share

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin